MiNK Therapeutics, Inc. (INKT) intrinsic value & 10-year financials
MiNK Therapeutics, Inc. (INKT) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $9.41
- Market cap
- $40.2M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 62.0%
- Free cash flow (FY2025)
- —
INKT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$12.5M | -$2.93 | — | — | 73.9% |
| FY2024 | — | -$10.8M | -$2.86 | — | — | 57.3% |
| FY2023 | — | -$22.5M | -$0.65 | -$15.8M | — | 243.4% |
| FY2022 | — | -$28.0M | -$0.83 | -$19.1M | — | -239.5% |
| FY2021 | — | -$30.2M | -$1.16 | -$13.1M | — | 200.8% |
| FY2020 | — | -$16.2M | — | -$8.4M | — | 36.0% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
MiNK Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
MiNK Therapeutics, Inc. has earned high returns on invested capital, averaging 28.2% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
MiNK Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
MiNK Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.